Assessment of the innovative quality of agomelatine through the Innovation Assessment Algorithm

Authors

  • Liliana Civalleri SIFEIT – Società Italiana per Studi di Economia ed Etica sul Farmaco e sugli Interventi Terapeutici [Italian Association for Research on the Economics and Ethics of Medications and Therapeutic Procedures], Rome
  • Sabrina Licata SIFEIT – Società Italiana per Studi di Economia ed Etica sul Farmaco e sugli Interventi Terapeutici [Italian Association for Research on the Economics and Ethics of Medications and Therapeutic Procedures], Rome

DOI:

https://doi.org/10.7175/fe.v13i3.279

Keywords:

Agomelatine, IAA, Innovation, Efficacy, Effectiveness

Abstract

Aim: the aim of this study was to assess the innovative quality of a medicine based on agomelatine, authorized by the European Commission through a centralized procedure on 19th February 2009 and distributed in Italy under the brands Valdoxan® and Thymanax®.

Methodology: the degree of innovation of agomelatine was determined through the Innovation Assessment Algorithm (IAA), which considers the innovative quality of a medicine as a combination of multiple properties. The algorithm may be represented as a decision tree, with each branch corresponding to a property connected with innovation and having a fixed numerical value. The sum of these values establishes the degree of innovation of the medicine. The IAA is articulated in two phases: the first assesses the efficacy of the drug based on the clinical trials presented in support of the registration application (IAA-efficacy); the second reconsiders the degree of innovation on the basis of the efficacy and safety data resulting from clinical practice once the drug has been placed on the market (IAA-effectiveness).

Results and conclusions: the score obtained for agomelatine was 592.73 in the efficacy phase and 291.3 in the effectiveness phase. The total score for the two phases was 884, which is equivalent to a good degree of innovation for the molecule

Downloads

Published

2012-09-21

Issue

Vol. 13 No. 3 (2012)

Section

Original Research

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
  4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)

How to Cite

1.
Civalleri L, Licata S. Assessment of the innovative quality of agomelatine through the Innovation Assessment Algorithm. Farmeconomia. Health Economics and Therapeutic Pathways. 2012;13(3):141-152. https://doi.org/10.7175/fe.v13i3.279

Most read articles by the same author(s)